Madrigal Pharmaceuticals Inc. (MDGL)
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MDGL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.81B
- Forward P/E
- 36.52
- EPS (TTM)
- -$5.85
- Dividend yield
- None
- 52-week range
- 353.54 – 615.00
- Day range
- 377.91 – 399.43
- Volume / Avg
- 327.83K / 370.07K
- Beta
- —
- Shares outstanding
- 23.23M
52-week range
MDGL stock today
Shares of Madrigal Pharmaceuticals (MDGL) finished lower on Nov 20 at $379.10, a drop of 4.45% or $17.64 per share, versus the S&P 500's 3.70% decline. At this level, MDGL sits near the bottom of its 52-week range of $353.54 to $615.00: 38.4% below the high, set on Dec 24, 2025 and 7.2% above the low. MDGL is down 34.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 30.8%.
Madrigal Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$5.85), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Madrigal Pharmaceuticals
Company profileMadrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. William J. Sibold
- Headquarters
- West Conshohocken, PA
- Employees
- 915
- IPO year
- 2007
- Website
- madrigalpharma.com
Financial highlights
Full financialsIn fiscal 2025, Madrigal Pharmaceuticals generated $958.4 million in revenue, up 432.1% from fiscal 2024, its 2nd consecutive year of revenue growth. Madrigal Pharmaceuticals reported a net loss of $288.3 million, compared with a loss of $465.9 million a year earlier. Operating margin was -31.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $958.40M | $180.13M | $0 | $0 | $0 |
| Growth | +432.05% | — | — | — | — |
| Net income | $-288.28M | $-465.89M | $-373.63M | $-295.35M | $-241.85M |
| EPS (diluted) | $-10.15 | $-17.31 | $-17.33 | $-17.23 | $-14.63 |
Analyst forecast
ForecastConsensus (19 analysts)
strong_buy
Avg. price target
$688.78+81.69%
- Strong buy 3
- Buy 15
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $1.83 vs $-1.09
- Surprise
- +267.89%
MDGL news
All MDGL news- MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity ConcernsPR Newswire
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLPPR Newswire
- Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor ConferencesGlobeNewswire
- Investigation of MDGL Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLPPR Newswire
- MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity ConcernsPR Newswire
- The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and MadrigalNasdaqBCRX, INSM, TGTX, MDGL
Madrigal Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SYRESpyre Therapeutics Inc. | 93.47 | -4.26% | $8.88B | vs MDGL |
| PRAXPraxis Precision Medicines Inc. | 300.43 | -3.37% | $8.40B | vs MDGL |
| TGTXTG Therapeutics Inc. | 63.34 | -2.37% | $9.57B | vs MDGL |
| SMMTSummit Therapeutics Inc. | 9.95 | -5.87% | $7.96B | vs MDGL |
| PTGXProtagonist Therapeutics Inc. | 121.40 | -2.11% | $7.92B | vs MDGL |
| RYTMRhythm Pharmaceuticals Inc. | 112.36 | -3.80% | $7.79B | vs MDGL |
| ALKSAlkermes plc | 44.94 | -2.69% | $7.55B | vs MDGL |
| KNSAKiniksa Pharmaceuticals International plc Class A | 93.90 | +0.38% | $7.38B | vs MDGL |
Indexes, lists and sector
Madrigal Pharmaceuticals stock FAQ
What is Madrigal Pharmaceuticals's stock price today?
MDGL last traded at $379.10 as of Nov 20, 4:00 PM EST, down 4.45% on the day. Prices are delayed at least 15 minutes.
Does Madrigal Pharmaceuticals pay a dividend?
No. Madrigal Pharmaceuticals does not currently pay a regular cash dividend.
Who is Madrigal Pharmaceuticals's CEO?
Mr. William J. Sibold is the chief executive officer of Madrigal Pharmaceuticals Inc., which has about 915 employees.
Has MDGL ever split its stock?
Yes. The most recent MDGL stock split was a 1-for-35 split on Jul 25, 2016.
What is the MDGL 52-week high?
The 52-week high for MDGL is $615.00 and the 52-week low is $353.54. The stock is currently 38.4% below its high.